

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
25 June 2020 (25.06.2020)



(10) International Publication Number
WO 2020/127503 A1

(51) International Patent Classification:

A61K 31/496 (2006.01) *C07D 471/04* (2006.01)
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
A61P 35/00 (2006.01)

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2019/085982

(22) International Filing Date:

18 December 2019 (18.12.2019)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1820582.3 18 December 2018 (18.12.2018) GB
1911007.1 01 August 2019 (01.08.2019) GB
1917701.3 04 December 2019 (04.12.2019) GB

(71) Applicants: **ARGENX BVBA** [BE/BE]; Industriepark Zwijnaarde 7, 9052 Gent (BE). **UNIVERSITY OF BERN** [CH/CH]; Verwaltungsdirektion, Hochschulstrasse 6, 3012 Bern (CH).

(72) Inventors: **DE HAARD, Hans**; c/o ARGENX BVBA, Industriepark Zwijnaarde 7, 9052 Gent (BE). **FUNG, Samson**; c/o ARGENX BVBA, Industriepark Zwijnaarde 7, 9052 Gent (BE). **LEUPIN, Nicolas**; c/o ARGENX BVBA, Industriepark Zwijnaarde 7, 9052 Gent (BE). **VAN ROMPAEY, Luc**; c/o ARGENX BVBA, Industriepark Zwijnaarde 7, 9052 Gent (BE). **OCHSENBEIN, Adrian**; c/o University of Bern, Verwaltungsdirektion, Hochschulstrasse 6, 3012 Bern (CH). **RIETHER, Carsten**; c/o University of Bern, Verwaltungsdirektion, Hochschulstrasse 6, 3012 Bern (CH).

(74) Agent: **BOULT WADE TENNANT LLP**; Salisbury Square House, 8 Salisbury Square, London Greater London EC4Y 8AP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: CD70 AND VENETOCLAX, A BCL-2 INHIBITOR, COMBINATION THERAPY FOR TREATING ACUTE MYELOID LEUKEMIA

(57) Abstract: The invention relates to combination therapies, particularly combination therapies for the treatment of myeloid malignancy. The combination therapies are particularly useful in methods for the treatment of acute myeloid leukemia (AML). The combination therapies include an antibody or antigen binding fragment thereof that binds to CD70 and a BCL-2 inhibitor, preferably venetoclax or a pharmaceutically acceptable salt thereof.

WO 2020/127503 A1